Analyst Josh Jennings of TD Cowen maintained a Buy rating on Vericel, retaining the price target of $55.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Josh Jennings has given his Buy rating due to a combination of factors including the promising growth potential of Vericel’s MACI Arthro platform. The adoption of this minimally invasive technique is expected to significantly boost the company’s MACI procedure volumes, driven by procedural efficiencies and increased patient awareness.
Jennings is confident that the MACI Arthro will sustain over 20% growth for Vericel’s MACI franchise. The recent approval and rollout of MACI Arthro across the US expands the target base of surgeons and enhances the company’s ability to penetrate the knee cartilage repair market. This expansion is crucial as it addresses a substantial portion of the $3 billion addressable market, particularly focusing on the common femoral condyle defect segment.